Physician profile
Neil Brody
NPI 1790768224
$12,022.26
in general payments reported to CMS, 2019-2025
27 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $299 · 2021: $922 · 2022: $5,152 · 2023: $1,672 · 2024: $1,482 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,402 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,402.23 |
| Education | $237.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $3,212.94 | 2022 | |
| Janssen Biotech, INC. | $1,563.67 | 2019-2025 | Tremfya, Simponi, Stelara |
| Merz North America, INC. | $1,471.94 | 2019-2025 | Xeomin |
| Lilly USA, LLC | $993.97 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $881.50 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $880.85 | 2021-2025 | Dupixent |
| Abbvie INC. | $675.44 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $510.59 | 2019-2024 | |
| Pfizer INC. | $271.07 | 2022-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $255.31 | 2023-2025 | Valchlor |
| Amgen INC. | $217.18 | 2019-2025 | Otezla |
| Ucb, INC. | $158.55 | 2019-2024 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $148.15 | 2023-2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Epizyme, INC. | $124.77 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $113.77 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $113.15 | 2021-2023 | Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $71.85 | 2024 | Vtama |
| Smith+Nephew, INC. | $63.64 | 2024 | Collagenase Santyl |
| Almirall LLC | $59.14 | 2021-2022 | |
| Organon LLC | $27.53 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $21.13 | 2023 | |
| Leo Pharma INC. | $19.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.45 | 2019 | |
| Journey Medical Corporation | $13.55 | 2022 | |
| Allergan, INC. | $13.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.